Aptevo Therapeutics Inc (APVO)
NASDAQ:APVO
Want to see APVO full AI Analyst Report?
APVO Stock Chart & Stats
$0.61
-$0.30(-5.81%)
At close: 4:00 PM EST
$0.61
-$0.30(-5.81%)
Day’s Range― - ―
52-Week Range$3.80 - $257.76
Previous CloseN/A
Volume25.11K
Average Volume (3M)11.64M
Market Cap
$5.73M
Enterprise Value-$7.01M
Total Cash (Recent Filing)$21.62M
Total Debt (Recent Filing)$4.63M
Price to Earnings (P/E)―
Beta-0.05
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1684.47
Shares Outstanding1,181,725
10 Day Avg. Volume7,942,705
30 Day Avg. Volume11,635,265
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-1.22
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit86.60
Enterprise Value/Ebitda0.27
Forecast
1Y Price Target
$21.00Price Target Upside3342.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-20.99
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Promising Interim AML Data For MipletamigRobust interim RAINIER results materially de-risk Aptevo's lead asset: high response and MRD-negativity rates in a fragile frontline AML cohort plus no CRS suggest differentiated safety/efficacy. This raises partner interest, improves regulatory/approval probability, and supports durable pathway to combinations and label expansion.
Proprietary ADAPTIR/ADAPTIR-FLEX PlatformsOwning multi-specific antibody engineering platforms provides a structural competitive advantage: enables repeatable design of differentiated biologics, broadens pipeline opportunity, supports licensing/collaboration revenues, and reduces binary dependence on a single molecule over the medium term.
Expanded Equity Financing Capacity ApprovedSecuring standby equity capacity is a durable financing benefit: it materially increases access to capital to fund clinical programs and operations, extending runway and reducing immediate insolvency risk. That structural financing option supports continued advancement of trials and strategic partnering efforts.
Bears Say
Zero Revenue And Sustained Operating LossesA multi-year absence of product revenue and ongoing operating losses mean the business cannot self-fund development. Continued reliance on external capital raises execution risk, can erode equity value, and makes long-term program funding contingent on market access or successful partnering.
Worsening Cash Burn And Negative Cash GenerationDeep and worsening negative cash flow is a structural constraint: it shortens runway, forces recurring capital raises, increases dilution risk, and can delay or curtail clinical programs. Without a clear path to positive cash generation, strategic options remain limited and financing costs rise.
Material Dilution Risk From Approved Equity FacilityWhile the equity facility improves funding access, authorizing issuance of >19.99% of shares creates meaningful dilution risk. Repeated or large draws could materially change ownership, reduce per-share economics for long-term holders, and influence capital-allocation decisions in ways that constrain shareholder value creation.
Aptevo Therapeutics News
APVO FAQ
What was Aptevo Therapeutics Inc’s price range in the past 12 months?
Aptevo Therapeutics Inc lowest stock price was $3.80 and its highest was $257.76 in the past 12 months.
What is Aptevo Therapeutics Inc’s market cap?
Aptevo Therapeutics Inc’s market cap is $5.73M.
When is Aptevo Therapeutics Inc’s upcoming earnings report date?
Aptevo Therapeutics Inc’s upcoming earnings report date is May 07, 2026 which is in 6 days.
How were Aptevo Therapeutics Inc’s earnings last quarter?
Aptevo Therapeutics Inc released its earnings results on Mar 26, 2026. The company reported $1684.47 earnings per share for the quarter, beating the consensus estimate of -$5.94 by $1690.41.
Is Aptevo Therapeutics Inc overvalued?
According to Wall Street analysts Aptevo Therapeutics Inc’s price is currently Undervalued.
Does Aptevo Therapeutics Inc pay dividends?
Aptevo Therapeutics Inc does not currently pay dividends.
What is Aptevo Therapeutics Inc’s EPS estimate?
Aptevo Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aptevo Therapeutics Inc have?
Aptevo Therapeutics Inc has 1,181,725 shares outstanding.
What happened to Aptevo Therapeutics Inc’s price movement after its last earnings report?
Aptevo Therapeutics Inc reported an EPS of $1684.47 in its last earnings report, beating expectations of -$5.94. Following the earnings report the stock price went up 1.921%.
Which hedge fund is a major shareholder of Aptevo Therapeutics Inc?
Currently, no hedge funds are holding shares in APVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
APVO Stock 12 Month Forecast
Average Price Target
$21.00
▲(3342.62% Upside)
Technical Analysis
Ownership Overview
1.15% Insiders
1.89% Mutual Funds
<0.01% Other Institutional Investors
95.89% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---